DIDO1

Across TCGA pan-cancer cohorts, DIDO1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DIDO1 data layer compared with 25 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DIDO1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DIDO1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where DIDO1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.571	0.838	<.001	105	view →
CCRCC	DFS	Median	II,III,IV	0.762	0.489	.011	16	view →
LUAD	OS	Median	III,IV	1.000	0.770	.006	13	view →
GBM	OS	Tertile	All	0.507	0.268	.011	6	view →
UCEC	DFS	Tertile	All	0.841	0.953	.039	2	view →
LSCC	OS	Median	II,III,IV	0.810	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DIDO1–HNSC (OS)

Open the HNSC breakdown →